Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Lukang Pharmaceutical Co's quarterly Total Liabilities
increased
from Sep. 2025 (¥4,711.54 Mil) to Dec. 2025 (¥4,777.41 Mil) but then
declined
from Dec. 2025 (¥4,777.41 Mil) to Mar. 2026 (¥4,570.27 Mil).
Shandong Lukang Pharmaceutical Co's annual Total Liabilities
declined
from Dec. 2023 (¥5,061.08 Mil) to Dec. 2024 (¥5,036.42 Mil) and
declined
from Dec. 2024 (¥5,036.42 Mil) to Dec. 2025 (¥4,777.41 Mil).
Shandong Lukang Pharmaceutical Co Total Liabilities Related Terms
Shandong Lukang Pharmaceutical Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Lukang Pharmaceutical Co Total Liabilities Chart
Shandong Lukang Pharmaceutical Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Lukang Pharmaceutical Co (SHSE:600789) has a Total Liabilities of ¥4,570 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Shandong Lukang Pharmaceutical Co and its competitors.
Is Shandong Lukang Pharmaceutical Co's Total Liabilities too high?
Shandong Lukang Pharmaceutical Co's current Total Liabilities is ¥4,570 Mil. Overall, Shandong Lukang Pharmaceutical Co has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shandong Lukang Pharmaceutical Co's Total Liabilities compare to ZTS and UTHR?
Shandong Lukang Pharmaceutical Co's Total Liabilities of ¥4,570 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Shandong Lukang Pharmaceutical Co and its competitors. Shandong Lukang Pharmaceutical Co's current Total Liabilities is ¥4,570 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Lukang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Lukang Pharmaceutical Co (SHSE:600789) is currently considered Fairly Valued. The stock's GF Value™ is ¥7.55, compared to a current price of ¥7.18 — trading 4.9% below its estimated fair value. The current Total Liabilities is ¥4,570 Mil. Shandong Lukang Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Shandong Lukang Pharmaceutical Co (SHSE:600789), the current Total Liabilities is ¥4,570 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Lukang Pharmaceutical Co (SHSE:600789) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Lukang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.18 is trading 4.9% below its estimated GF Value™ of ¥7.55.
GuruFocus considers Shandong Lukang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600789:
Total Liabilities: ¥4,570 Mil
GF Value™: ¥7.55 vs. price of ¥7.18 (4.9% below fair value)
No single metric tells the full story. See the SHSE:600789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Lukang Pharmaceutical Co Business Description
Shandong Lukang Pharmaceutical Co Ltd is a bio-pharmaceuticals company. It is engaged in manufacturing antibiotics, semi-synthetic antibiotics for human use, bio-pharmaceuticals for veterinary and agriculture use, intermediates, resins, starches, glucose and amino acids.
67GF Score
Get the complete analysis for SHSE:600789
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600789 has been successfully added to your 
